OpenText To Acquire Micro Focus International plc For $6B

About the Terms of the Acquisition (all figures approximate)

About the Terms of the Acquisition (all figures approximate)

  • Total purchase price of $6.0 billion, inclusive of Micro Focus’ cash and debt
  • Total purchase price is 2.2x Micro Focus’ pro forma TTM revenues(1)
  • Total purchase price is 6.3x Micro Focus’ pro forma TTM adjusted EBITDA(4)
  • Expected cost synergies of $400 million, including Micro Focus’ previously announced cost savings program of $300 million (net of inflation), as well as $100 million in additional cost synergies
  • Targeting to be on the OpenText operating model within 6 quarters of closing
  • Expect meaningful expansion of cloud revenues, adjusted EBITDA and cash flows in Fiscal 2024
  • All-cash consideration for the Acquisition to be funded by $4.6 billion in new debt, $1.3 billion in cash, and a $600 million draw on our existing revolving credit facility
  • The Announcement can be found on our website at https://investors.opentext.com. This press release should be read in conjunction with, and is subject to, the full text of the Announcement.
  • The Acquisition is expected to close in the first quarter of calendar 2023, subject to the satisfaction (or, where applicable, waiver) of the conditions set out in Appendix 1 to the Announcement.
Total
0
Shares
Related Posts
Read More

Aurora Touts 41% YoY Increase In International Medical Cannabis Q3 Revenue, Expands In Australia Via New Acquisition

Canadian medical cannabis company Aurora Cannabis reported its financial and operational results for Q3 2024. Net revenue increased to CAD64.4m ($42m), up from CAD61.1m in the same quarter the previous year. Medical cannabis net revenue rose by 16% to CAD45.1m, representing 70% of Aurora's consolidated net revenue. Gross profit reached CAD19.8m, up from CAD3.7m in Q3 2022, with adjusted gross profit before fair value adjustments increasing to CAD32.4m from CAD28m. The company recorded a CAD25.5m net loss compared to CAD67.2m in the same quarter in the previous year. Adjusted EBITDA came in at CAD4.3m, up from CAD3m. Miguel Martin, CEO of Aurora, said the company's international medical net revenue had seen year-on-year growth of 41%.

ACB